Literature DB >> 23406918

White matter hyperintensities and functional outcomes at 2 weeks and 1 year after stroke.

Hee-Ju Kang1, Robert Stewart, Man-Seok Park, Kyung-Yeol Bae, Sung-Wan Kim, Jae-Min Kim, Il-Seon Shin, Ki-Hyun Cho, Jin-Sang Yoon.   

Abstract

BACKGROUND: Many stroke survivors remain at a functionally disabled state. Early prediction of functional outcome is an important step in the treatment and care of stroke patients. Brain imaging measures have received particular attention as one of the predictors of stroke outcomes. However, the associations between white matter hyperintensities (WMHs) and post-stroke recovery have been controversial. This study aimed to investigate whether deep and periventricular WMHs (DWMHs and PVWMHs, respectively) were associated with functional outcomes at 2 weeks and 1 year after stroke separately and interactively.
METHODS: A total of 408 patients were evaluated at the time of admission and 2 weeks after stroke, and 284 (78%) were followed 1 year later in order to evaluate consequences of stroke at both acute and chronic stages. Stroke outcomes were dichotomized into good and poor by applying a modified Rankin Scale (mRS) score cutoff of 1 (no significant disability)/2 (slight disability). Measures of stroke severity (National Institutes of Health Stroke Scale: NIHSS), physical disability (Barthel Index: BI), and cognitive function (Mini-Mental State Examination: MMSE) were administered. Brain magnetic resonance imaging (MRI) was performed at admission. DWMHs and PVWMHs were rated visually on axial FLAIR images using the 4-point modified Fazeka's scale and categorized into mild (grades 0 and 1) or severe (grades 2 and 3). The demographic and clinical covariates of age, gender, years of education, previous history of stroke, depression, stroke location, and vascular risk factors were obtained. Associations of WMHs with stroke outcomes (mRS) and other measures (NIHSS, BI, and MMSE) at 2 weeks and at 1 year after stroke were investigated using logistic regression and repeated measures ANOVA after adjustment for the potential covariates.
RESULTS: Severe PVWMHs, but not severe DWMHs, were significantly associated with worse outcomes both at 2 weeks and at 1 year after stroke. Furthermore, significant interactive effects of PVWMHs and DWMHs on poor outcomes were found. Significant PVWMH group by time interactions on NIHSS and BI scores, and significant group effects of both DWMHs and PVWMHs on MMSE score were found.
CONCLUSIONS: PVWMHs predicted poorer functional outcomes after stroke both in the acute and chronic phases, independently and interactively with DWMHs. In addition, PVWMHs were independently associated with worsening of stroke severity and physical disability. More careful evaluation and management of stroke patients with a high risk of functional dependence are indicated. Overall, PVWMH might be a prognostic marker of short- and long-term stroke outcomes.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2013        PMID: 23406918     DOI: 10.1159/000346604

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  15 in total

Review 1.  Recent Advances in Leukoaraiosis: White Matter Structural Integrity and Functional Outcomes after Acute Ischemic Stroke.

Authors:  Mark R Etherton; Ona Wu; Natalia S Rost
Journal:  Curr Cardiol Rep       Date:  2016-12       Impact factor: 2.931

2.  European Stroke Organisation and European Academy of Neurology joint guidelines on post-stroke cognitive impairment.

Authors:  Terence J Quinn; Edo Richard; Yvonne Teuschl; Thomas Gattringer; Melanie Hafdi; John T O'Brien; Niamh Merriman; Celine Gillebert; Hanne Huyglier; Ana Verdelho; Reinhold Schmidt; Emma Ghaziani; Hysse Forchammer; Sarah T Pendlebury; Rose Bruffaerts; Milija Mijajlovic; Bogna A Drozdowska; Emily Ball; Hugh S Markus
Journal:  Eur Stroke J       Date:  2021-10-08

3.  Leukoaraiosis predicts a poor 90-day outcome after endovascular stroke therapy.

Authors:  J Zhang; A S Puri; M A Khan; R P Goddeau; N Henninger
Journal:  AJNR Am J Neuroradiol       Date:  2014-07-03       Impact factor: 3.825

4.  Quantitative microstructural deficits in chronic phase of stroke with small volume infarcts: A diffusion tensor 3-D tractographic analysis.

Authors:  Prachi Dubey; Vasileios-Arsenios Lioutas; Rafeeque Bhadelia; Brad Manor; Peter Novak; Magdy Selim; Vera Novak
Journal:  Magn Reson Imaging       Date:  2015-12-30       Impact factor: 2.546

5.  White matter disease as a biomarker for long-term cerebrovascular disease and dementia.

Authors:  Aurauma Chutinet; Natalia S Rost
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-03

Review 6.  What are white matter hyperintensities made of? Relevance to vascular cognitive impairment.

Authors:  Joanna M Wardlaw; Maria C Valdés Hernández; Susana Muñoz-Maniega
Journal:  J Am Heart Assoc       Date:  2015-06-23       Impact factor: 5.501

7.  Relative risk values of age, acrolein, IL-6 and CRP as markers of periventricular hyperintensities: a cross-sectional study.

Authors:  Arata Abe; Yasuhiro Nishiyama; Mina Harada-Abe; Seiji Okubo; Masayuki Ueda; Masahiro Mishina; Yasuo Katayama
Journal:  BMJ Open       Date:  2014       Impact factor: 2.692

Review 8.  Comorbidity of depression with physical disorders: research and clinical implications.

Authors:  Hee-Ju Kang; Seon-Young Kim; Kyung-Yeol Bae; Sung-Wan Kim; Il-Seon Shin; Jin-Sang Yoon; Jae-Min Kim
Journal:  Chonnam Med J       Date:  2015-04-14

9.  Imaging predictors of poststroke depression: methodological factors in voxel-based analysis.

Authors:  Sophia A Gozzi; Amanda G Wood; Jian Chen; Krishnarao Vaddadi; Thanh G Phan
Journal:  BMJ Open       Date:  2014-07-07       Impact factor: 2.692

10.  The Additional Contribution of White Matter Hyperintensity Location to Post-stroke Cognitive Impairment: Insights From a Multiple-Lesion Symptom Mapping Study.

Authors:  Lei Zhao; Adrian Wong; Yishan Luo; Wenyan Liu; Winnie W C Chu; Jill M Abrigo; Ryan K L Lee; Vincent Mok; Lin Shi
Journal:  Front Neurosci       Date:  2018-05-01       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.